logo-loader
viewZelira Therapeutics Ltd

Zelda Therapeutics "ahead of the pack" in gaining first-mover advantages

Zelda Therapeutics Ltd (ASX:ZLD) executive chairman Harry Karelis updates Proactive Investors on the company’s global operations, following a January dual listing on the OTCQB Venture Market in the United States (OTCQB: ZLDAF).

“We have a two-pronged strategy. One is the clinical trials where we know there is some kind of effect, whether that's autism or pain or insomnia, so that's our clinical arm; and our pre-clinical arm is really spending money with some of the world's best researchers in studying cannabis as an anti-cancer agent… if we can replicate in the lab some of these anti-cancer effects then we believe that adds quite a lot of value for shareholders in Zelda in terms of then partnering with a traditional bio-pharmaceutical company... the data that we're generating and the intellectual property that we're developing is of value to those big bio-pharmaceutical companies that are geared up financially and otherwise for running these big complex trials," says Karelis.

Quick facts: Zelira Therapeutics Ltd

Price: 0.053 AUD

ASX:ZLD
Market: ASX
Market Cap: $51.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 02/21/2020

2 min read